Feb 24 (Reuters) - Summit Therapeutics Inc SMMT.O:
SUMMIT THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH PFIZER TO EVALUATE IVONESCIMAB IN COMBINATION WITH PFIZER ANTIBODY DRUG CONJUGATES (ADCS)
SUMMIT THERAPEUTICS - UNDER TERMS OF AGREEMENT, CO TO PROVIDE IVONESCIMAB, PFIZER TO CONDUCT STUDY OPERATIONS
SUMMIT THERAPEUTICS INC - CLINICAL TRIALS EXPECTED TO START MID-YEAR
Source text: ID:nBw9j279fa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.